273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
The Readout Loud
00:00
Reflections on transitioning to the sell side
The speaker shares their experience transitioning from Allogene to Cantor and highlights the importance of paying attention to SEC filings and vetted documents for uncovering valuable information. The chapter ends with gratitude towards the podcast guests.
Transcript
Play full episode
